Home » FDA Rejects Appeal Regarding Genasense
FDA Rejects Appeal Regarding Genasense
Genta Incorporated announced that the FDA Center for Drug Evaluation and Research has decided that available data are not adequate to support approval of Genasense (oblimersen sodium) Injection for treatment of patients with relapsed or refractory chronic lymphocytic leukemia.
TradingMarkets
TradingMarkets
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May